Abstract
Introduction

Immune cells can be divided into innate (myeloid) and adaptive (lymphoid) cells. Innate immune cells, including macrophages, polymorphonuclear granulocytes (neutrophils, basophils and eosinophils) mast cells, dendritic cells (DC), natural killer (NK) cells and platelets represent the first line of defence against pathogens and foreign agents. The innate immune cells can directly eliminate pathogenic agents in situ. DCs, on the other hand, take up foreign antigens and migrate to lymphoid organs where they present their antigens to adpative immune cells. Adaptive immune cells are lymphocytes (T and B cells), which undergo clonal expansion and elaborate an adaptive response targeted to the foreign agent. Whereas the cells of the innate immune system are found in the blood stream and in most organs of the body, lymphocytes are localized to specialized organs and tissues. There is tight interplay between innate immune cells and the vascular system. Endothelial cells mediate immune cell recruitment to extravascular tissues by expressing a repertoire of leucocyte adhesion molecules. On the other hand, innate immune cells synthesize a number of soluble factors that influence endothelial cell behaviour. Recruitment of an inflammatory infiltrate supports angiogenesis and tissue remodelling.
The importance of angiogenesis in physiological and pathological conditions
Angiogenesis, i.e. the formation of new vessels from pre-existing ones such as capillaries and post-capillary venules, plays a pivotal role during embryonal development [1] and later, in adult life, in several physiological (e.g. corpus luteum formation) and pathological conditions, such as tumour and chronic inflammation, where angiogenesis itself may contribute to the progression of disease. In 1971, Folkman published in the 'New England Journal of Medicine' a hypothesis that tumour growth is angiogenesis-dependent and that inhibition of angiogenesis could be therapeutic
. This paper also introduced the term anti-angiogenesis to mean the prevention of new vessel sprout from being recruited by a tumour. The hypothesis predicted that tumours would be enable to grow beyond a microscopic size of 1 to 2 mm 3 [3] .
without continuous recruitment of new capillary blood vessels. This concept is now widely accepted because of supporting data from experimental studies and clinical observations carried out over the intervening years
The process of angiogenesis begins with local degradation of the basement membrane surrounding the capillaries, which is followed by invasion of the surrounding stroma by the underlying endothelial cells, in the direction of the angiogenic stimulus. Endothelial cells migration is accompanied by the proliferation of endothelial cells and their organization into three-dimensional structures that join
with other similar structures to form a network of new blood vessels [1] . Angiogenic factors are potent growth factors that promote proliferation and differentiation of endothelial cells. The major angiogenic and anti-angiogenic factors are listed in Table 1 .
Under physiological conditions, angiogenesis is dependent on the balance of positive and negative angiogenic modulators within the vascular microenvironment [4] [6] .
The contribution of immune cells to angiogenesis in inflammation and tumour growth
There is increasing evidence to support the view that angiogenesis and inflammation are mutually dependent [7] . During inflammatory reactions, immune cells synthesize and secrete pro-angiogenic factors that promote neovascularization. On the other hand, the newly formed vascular supply contributes to the perpetuation of inflammation by promoting the migration of inflammatory cells to the site of inflammation [7] . The [53] , glioma [54] , squamous cell carcinoma of the esophagus [55] , bladder carcinoma [56] , and prostate carcinoma [57] . [58] . In one model of subcutaneous melanoma, both angiogenesis and growth rate correlate with tumour infiltration by macrophages that express angiotensin I receptor and VEGF [59] [63] . Moreover, activated macrophages synthesize and release inducible nitric oxide synthase, which increases blood flow and promotes angiogenesis [64] . Last, the angiogenic factors secreted by macrophages stimulate migration of other accessory cells that potentiate angiogenesis, in particular mast cells [65] . Osteopontin deeply affects the pro-angiogenic potential of human monocytes [66] . Reports suggest that osteopontin may affect angiogenesis by acting directly on endothelial cells and/or indirectly via mononuclear phagocyte engagement, enhancing the expression of TNF-␣ and IL-1-␤ in mononuclear cells [67, 68] .
inhibitor of IL-8-, macrophage inflammatory protein (MIP)-2-and growth-related oncogen-␣ (GRO-␣)-induced angiogenesis in vivo [30]. Remarkably, all-trans retinoic acid, a promising molecule with potential anti-angiogenic use in clinical treatment, has been shown to inhibit VEGF formation in cultured neutrophil-like HL-60 cells [31].
Basophils
Basophils express mRNA for three isoforms of VEGF-A (121, 165 and 189) and two isoforms of VEGF-B (167 and 186) [32]. Peripheral blood and basophils infiltrating sites of chronic inflammation such as nasal polyps contain VEGF-A in their secretory granules. Supernatants of activated basophils induced an angiogenic response in vivo in the chick embryo chorioallantoic membrane (CAM) assay. In addition, basophils express VEGF receptor-2 (VEGFR-2) and neuropilin-1 that acts as co-receptor for VEGFR-2 and enhances VEGFR-2-induced responses. Remarkably, VEGF-
Monocytes-macrophages
In the mouse cornea model, killing of COX-2 positive infiltrating macrophages with clodronate liposomes reduces IL-1-␤-induced angiogenesis and partially inhibits VEGF-induced angiogenesis
It should also be mentioned that monocytes and macrophages are primary producers of IL-12. This multifunctional cytokine can cause tumour regression and reduce metastasis in animal models, because of the promotion of anti-tumour immunity and also to the significant inhibition of angiogenesis [69] . [78] . receptors indeed are present primarily on NK cells and T cells [79] . [80] . [81] . They participate in the regulation of the inflammatory reaction through the release of cytokines and chemokines [82] . [84] . Riboldi et al. [85] [89] . [90] [91] [92] [93] [96, 97] . [100, 101] . Human mast cells are a potent source of VEGF in the absence of degranulation through activation of the EP (2) receptor by PGE2 [102] . Following IgE-dependent activation mast cells released several pro-angiogenic mediators stored in their granules, such as VEGF [103] and FGF-2 [104] , that promote angiogenesis even in the early phase of allergic inflammation. Mast cells can also migrate in vivo [105] and in vitro [65] in response to VEGF. Recently, Detoraki et al. [106] [106] . [107] . Similarly it has been demonstrated, using the rat-mesenteric window angiogenic assay, that intraperitoneal injection of compound 48/80 causes a vigorous angiogenic response [108] . The same treatment in mice also causes angiogenesis [109] .
IL-12-activated lymphocytes influence inhibition of tumour growth and function as an anti-vascular agent, by releasing higher level of IFN-␥ and down-modulating VEGF
Dendritic cells
DCs are bone marrow, hematopoietic-derived, professional antigen-presenting cells (APCs), able to induce both primary and secondary T-and B-cell responses as well as immune tolerance
DCs express both pro-and anti-angiogenic mediators when exposed to different combinations of cytokines and microbial stimuli and both positive and negative mediators of the angiogenic process can affect the biology of DCs. DCs express both VEGFR-1 and VEGFR-2 [83]. Furthermore, expression of the VEGF co-receptor neuropilin-1 is induced during in vitro differentiation of monocytes into DCs
reported that DCs can be activated to an angiogenesis-promoting phenotype. They demonstrated that alternative activation of DCs by anti-inflammatory molecules, such as calcitriol, prostaglandin E2 (PGE2) or IL-10 prompts them to secrete VEGF and inhibit their secretion of IL-12, a potent antiangiogenic molecule that is secreted by classical activated DCs.
The contribution of progenitor cells and adult cell transdifferentiation
Myeloid-derived suppressor cells (MDSCs) are a heterogenous population, comprising myeloid progenitors, monocytes and neutrophils that express low to undetectable levels of MHC-II and costimulatory molecules. Yang et al. [86] found that MDSCs obtained from spleens of tumour-bearing mice promoted angiogenesis and tumour growth when co-injected with tumour cells. Reducing the levels of MDSCs by either treatment of mice with gemcitabine or by interfering with the Kit ligand/c-Kit receptor axis impaired tumour growth and angiogenesis [87, 88]. MDSCs isolated from tumours of STAT-3-deficient mice were markedly less potent in inducing endothelial tube formation in vitro as compared to STAT-3 wild-type cells, concomitant with markedly reduced exepression levels of several angiogenic factors
Monocytes-macrophages and endothelial cells share phenotypical and functional features, including the expression of common metabolic and surface markers, as well as the ability to transdifferentiate into endothelial cells in vitro and in vivo
Mast cells
An increased number of mast cells have been reported in angiogenesis associated with chronic inflammatory diseases, like rheumatoid arthritis and nasal polyps
Mast cells produce a large spectrum of pro-angiogenic factors. Human, rat and mouse mast cells release preformed FGF-2 from their secretory granules [98, 99]. Human cord bloodderived mast cells release VEGF upon stimulation through FcεRI and c-kit. Both FGF-2 and VEGF have also been identified by immunohistochemistry in mature mast cells in human tissues
have demonstrated that human lung mast cells express VEGF-A, VEGF-B, VEGF-C and VEGF-D at both mRNA and protein level. PGE2 enhanced the expression of VEGF-A, VEGF-B and VEGF-C, whereas an adenosine analogue (5'-[N-ethylcarboxamido] adenosine [NECA]) increased VEGF-A, VEGF-C and VEGF-D expression. In addition, supernatants of PGE2-and NECA-activated human lung mast cells induced angiogenic response in the CAM assay that was inhibited by an anti-VEGF-A antibody. Finally, placental growth factor-1 induced mast cell chemotaxis
Granulated mast cells and their granules, but not degranulated mast cells, are able indeed to stimulate an intense angiogenic reaction in the chick embryo CAM assay. This angiogenic activity is partly inhibited by anti-FGF-2 and -VEGF antibodies, suggesting that these cytokines are involved in the angiogenic reaction
Mast cells store large amounts of preformed active serine proteases, such as tryptase and chymase, in their secretory granules [110] . Tryptase [120, 121] , colorectal cancer [122] and uterine cervix cancer [123] . Tryptase-positive mast cells increase in number and vascularization increases in a linear fashion from dysplasia to invasive cancer of the uterine cervix [124] . An association of VEGF and mast cells with angiogenesis has been demonstrated in laryngeal carcinoma [125] and in small lung carcinoma, where most intratumoural mast cells express VEGF [126] [127] [128] . Mast cell accumulation has also been noted repeatedly around melanomas, especially invasive melanoma [129, 130] . Mast cell accumulation was correlated with increased neovascularization, mast cell expression of VEGF [131] and FGF-2 [132] , tumour aggressiveness and poor prognosis. Indeed, a prognostic significance has been attributed to mast cells and microvascular density not only in melanoma [133] but also in squanous cell cancer of the oesophagus [134] . Recently, angiogenesis has been shown to correlate with tryptase-positive mast cell count in human endometrial cancer. Both parameters were found to increase in agreement with tumour progression [135] . lymphadenopathies and B-cell non-Hodgkin's lymphomas, angiogenesis correlates with total and tryptase-positive mast cell counts, and both increase in step with the increase with malignancy grades [136, 137] . In non-Hodgkin's lymphomas, a correlation has been found between vessel count and the number of mast cells and VEGF-expressing cells [138] . In the bone marrow of patients with inactive and active multiple myeloma as well as those with monoclonal gammopathies of undetermined significance, angiogenesis highly correlates with mast cell counts [139] . A similar pattern of correlation between bone marrow microvessel count, total and tryptase-positive mast cell density and tumour progression has been found in patients with myelodysplastic syndrome [140] and B-cell chronic lymphocytic leukemia [141] . In the early stages of B-cell chronic lymphocytic leukemia, the density of tryptase-positive mast cells in the bone marrow has been shown to predict the outcome of the disease [142] . 
Mast cell density, new vessel rate and clinical prognosis have also been found to correlate in haematological tumours. In benign
